Señales en vivo de ERYP | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (28 jun 2023 @ 15:48):

ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States...

Stats
Volumen de hoy	3 205.00
Volumen promedio	148 586
Capitalización de mercado	47.38M
EPS	$0 ( 2023-04-26 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-78.00
ATR14	$0.108 (13.85%)

Volumen Correlación

Largo: 0.13 (neutral)

Corto: -0.16 (neutral)

Signal:(42.503) Neutral

Erytech Pharma S.A. Correlación

10 Correlaciones Más Positivas
DGHI	0.897
ITMR	0.884
AVEO	0.874
SOHON	0.868
CHDN	0.859
DVCR	0.851
SOHOB	0.848
XLO	0.847
BTBT	0.846
KIN	0.846

10 Correlaciones Más Negativas
AMRB	-0.873
SABS	-0.861
ORRF	-0.857
VTIP	-0.857
TRIB	-0.846
POLA	-0.837
SGMA	-0.833
SOPA	-0.816
MMAC	-0.814
LFMD	-0.809

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Erytech Pharma S.A. Correlación - Moneda/Commodity

-0.24
( neutral )

-0.31
( neutral )

0.00
( neutral )

-0.17
( neutral )

0.32
( neutral )

0.11
( neutral )

Erytech Pharma S.A. Finanzas

Annual	2022
Ingresos:	$0
Beneficio Bruto:	$0 (0.00 %)
EPS:	$-0.00740

FY	2022
Ingresos:	$0
Beneficio Bruto:	$0 (0.00 %)
EPS:	$-0.00740

FY	2021
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-2.68

FY	2020
Ingresos:	$0.00
Beneficio Bruto:	$-57.58M (0.00 %)
EPS:	$-3.65

Financial Reports:

No articles found.

Erytech Pharma S.A.

ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. The company was incorporated in 2004 and is headquartered in Lyon, France.